These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8011517)

  • 1. Abnormal factor VIII Hiroshima: defect in crucial proteolytic cleavage by thrombin at Arg1689 detected by a novel ELISA.
    Kamisue S; Shima M; Nishimura T; Tanaka I; Nakai H; Morichika S; Takata N; Kuramoto A; Yoshioka A
    Br J Haematol; 1994 Jan; 86(1):106-11. PubMed ID: 8011517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An arginine to cysteine amino acid substitution at a critical thrombin cleavage site in a dysfunctional factor VIII molecule.
    Shima M; Ware J; Yoshioka A; Fukui H; Fulcher CA
    Blood; 1989 Oct; 74(5):1612-7. PubMed ID: 2506948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor VIII Ise (R2159C) in a patient with mild hemophilia A, an abnormal factor VIII with retention of function but modification of C2 epitopes.
    Suzuki H; Shima M; Arai M; Kagawa K; Fukutake K; Kamisue S; Nakai H; Morichika S; Tanaka I; Inoue M; Gale K; Tuddenham EG; Yoshioka A
    Thromb Haemost; 1997 May; 77(5):862-7. PubMed ID: 9184393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purification and characterization of factor VIII 372-Cys: a hypofunctional cofactor from a patient with moderately severe hemophilia A.
    O'Brien DP; Pattinson JK; Tuddenham EG
    Blood; 1990 Apr; 75(8):1664-72. PubMed ID: 2109644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor VIII S373L: mutation at P1' site confers thrombin cleavage resistance, causing mild haemophilia A.
    Johnson DJ; Pemberton S; Acquila M; Mori PG; Tuddenham EG; O'Brien DP
    Thromb Haemost; 1994 Apr; 71(4):428-33. PubMed ID: 8052958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct characterization of factor VIII in plasma: detection of a mutation altering a thrombin cleavage site (arginine-372----histidine).
    Arai M; Inaba H; Higuchi M; Antonarakis SE; Kazazian HH; Fujimaki M; Hoyer LW
    Proc Natl Acad Sci U S A; 1989 Jun; 86(11):4277-81. PubMed ID: 2498882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acidic Region Residues 1680-1684 in the A3 Domain of Factor VIII Contain a Thrombin-Interactive Site Responsible for Proteolytic Cleavage at Arg1689.
    Nakajima Y; Minami H; Nogami K
    Thromb Haemost; 2021 Oct; 121(10):1274-1288. PubMed ID: 33592631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An alloantibody recognizing the FVIII A1 domain in a patient with CRM reduced haemophilia A due to deletion of a large portion of the A1 domain DNA sequence.
    Shibata M; Shima M; Morichika S; McVey J; Tuddenham EG; Tanaka I; Suzuki H; Nogami K; Minamoto Y; Hato T; Saenko EL; Scandella D; Yoshioka A
    Thromb Haemost; 2000 Sep; 84(3):442-8. PubMed ID: 11019969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cysteamine enhances the procoagulant activity of Factor VIII-East Hartford, a dysfunctional protein due to a light chain thrombin cleavage site mutation (arginine-1689 to cysteine).
    Aly AM; Arai M; Hoyer LW
    J Clin Invest; 1992 May; 89(5):1375-81. PubMed ID: 1569180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a thrombin cleavage site mutation (Arg 1689 to Cys) in the factor VIII gene of two unrelated patients with cross-reacting material-positive hemophilia A.
    Arai M; Higuchi M; Antonarakis SE; Kazazian HH; Phillips JA; Janco RL; Hoyer LW
    Blood; 1990 Jan; 75(2):384-9. PubMed ID: 2104766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purification and characterization of factor VIII 1,689-Cys: a nonfunctional cofactor occurring in a patient with severe hemophilia A.
    O'Brien DP; Tuddenham EG
    Blood; 1989 Jun; 73(8):2117-22. PubMed ID: 2499363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRM+ haemophilia A due to a missense mutation (372----Cys) at the internal heavy chain thrombin cleavage site.
    Pattinson JK; McVey JH; Boon M; Ajani A; Tuddenham EG
    Br J Haematol; 1990 May; 75(1):73-7. PubMed ID: 1973901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy.
    Gilmore R; Harmon S; Gannon C; Byrne M; O'Donnell JS; Jenkins PV
    Haemophilia; 2010 Jul; 16(4):671-4. PubMed ID: 20148980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A monoclonal antibody to factor VIII inhibits von Willebrand factor binding and thrombin cleavage.
    Precup JW; Kline BC; Fass DN
    Blood; 1991 May; 77(9):1929-36. PubMed ID: 1902121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine.
    Shima M; Scandella D; Yoshioka A; Nakai H; Tanaka I; Kamisue S; Terada S; Fukui H
    Thromb Haemost; 1993 Mar; 69(3):240-6. PubMed ID: 7682339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoblot analysis shows changes in factor VIII inhibitor chain specificity in factor VIII inhibitor patients over time.
    Fulcher CA; Lechner K; de Graaf Mahoney S
    Blood; 1988 Oct; 72(4):1348-56. PubMed ID: 2458782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor VIII-East Hartford (arginine 1689 to cysteine) has procoagulant activity when separated from von Willebrand factor.
    Aly AM; Hoyer LW
    J Clin Invest; 1992 May; 89(5):1382-7. PubMed ID: 1569181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteolysis at Arg740 facilitates subsequent bond cleavages during thrombin-catalyzed activation of factor VIII.
    Newell JL; Fay PJ
    J Biol Chem; 2007 Aug; 282(35):25367-75. PubMed ID: 17595160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain.
    Foster PA; Fulcher CA; Houghten RA; de Graaf Mahoney S; Zimmerman TS
    J Clin Invest; 1988 Jul; 82(1):123-8. PubMed ID: 2839543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular basis for cross-reacting material-positive hemophilia A due to missense mutations within the A2-domain of factor VIII.
    Amano K; Sarkar R; Pemberton S; Kemball-Cook G; Kazazian HH; Kaufman RJ
    Blood; 1998 Jan; 91(2):538-48. PubMed ID: 9427707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.